This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Nevro (NVRO) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Zacks Investment Ideas feature highlights: Henry Schein, AmerisourceBergen and McKesson
by Zacks Equity Research
Henry Schein, AmerisourceBergen and McKesson are included in this Investment Ideas blog.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) on increased demand for sleep and respiratory care devices on steady recovery of markets from COVID-19 impacts.
The Stock-Picking Puzzle: Putting The Pieces Together
by Bryan Hayes
The Stock-Picking Puzzle: Putting The Pieces Together
Here's Why You Should Add Quidel (QDEL) Stock To Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.
Zimmer Biomet (ZBH) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
According to Zimmer Biomet (ZBH), both Q4 net sales and earnings metrics are negatively impacted by China VBP in Knees, Hips and S.E.T. product categories.
Cerner (CERN) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.
3 Medical Products Stocks Poised to Beat This Earnings Season
by Trina Mukherjee
The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.
Illumina (ILMN) to Address Nasopharynx Cancer With New Pact
by Zacks Equity Research
Illumina's (ILMN) recent collaboration will fuel initiatives that enhance health outcomes for people living with nasopharynx cancer and advance the development of personalized treatment.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Sustained momentum with respect to inpatient dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the fourth quarter despite the ongoing pandemic-led business challenges.
Cardiovascular Systems' (CSII) Q2 Earnings Lag Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) exhibits a robust performance by its worldwide coronary franchise despite challenging business climate.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
Doximity (DOCS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Doximity's (DOCS) fiscal third-quarter results are likely to reflect growth in its telehealth platform and robust net revenue retention rate.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.
Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) Q4 top line.
Medtronic (MDT) Cardiovascular Line Rebounds, Spine Stays Soft
by Zacks Equity Research
Medtronic (MDT) is registering organic growth in the Cardiovascular, Neuroscience and Diabetes segments.
LabCorp (LH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development Q4 results are expected to reflect an increase in organic revenues on base business growth and contribution from COVID testing performed through the central lab.
Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Impressive performance by Hologic's (HOLX) Breast Imaging and Interventional Breast Solutions drove Q1 revenues.
What's in Store for Canopy Growth (CGC) in Q3 Earnings?
by Zacks Equity Research
New product launches across the CBD product portfolio and robust demand for legal cannabis products are likely to drive Canopy Growth's (CGC) Q3 top line.
Quest Diagnostics (DGX) Q4 Revenues Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics' (DGX) base business revenues grew year over year, achieving record levels in the fourth quarter.
Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Robust segmental growth and iTero sales are driving Align Technology's (ALGN) Q4 top line.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its progress in the WAVE study and a strong product portfolio.
Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Thermo Fisher's (TMO) Q4 earnings surpassed the Zacks Consensus Estimate with strength across the Analytical Instruments segment driving the top line.
IDEXX (IDXX) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.